Join to access to all OVN content. Join for Free
Role of the MSL in launch preparedness for new products and indications
MSL roles drug launch preparation medical affairs strategy pharmaceutical trends field medical leadership

Role of the MSL in launch preparedness for new products and indications


Share This Article


Summary

Matt Goodwin joins Tom Caravela to discuss the crucial role of MSLs in drug launch preparation and leadership. Matt shares his career journey and insights from his experiences at MAPS. They delve into the training, expectations, and success factors for MSLs during launches, addressing common stressors and establishing key milestones. The conversation highlights common pitfalls and offers advice for MSLs navigating launch phases. They examine the skills and motivation needed for evaluating MSL candidates and discuss future trends in pharma and MSL roles. The episode concludes with a call for listener feedback and subscription.

Matt Goodwin, Vice President Medical Affairs at SC Pharmaceuticals discusses the role of the MSL in preparation and strategy for launch preparedness of new products/indications.

Learn more about…

👉 The importance of preparation and timeline for launch
👉 Training and resources for launch mode
👉 The role of field medical leadership
👉 Milestones and success factors to consider
👉 The stressors to be aware of and anticipate during a launch

Click for Source
MSL roles, drug launch preparation, medical affairs strategy, pharmaceutical trends, field medical leadership

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
No “D”…No Problem: Finding Success WITHOUT a Doctorate
Partner Avatar MSL Talk: Tom Caravela, Greg Auclair

No “D”…No Problem: Finding Success WITHOUT a Doctorate

Podcast
Motivation Means NOTHING…
Partner Avatar MSL Talk: Tom Caravela

Motivation Means NOTHING…

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN